AI Consensus Investment Thesis
Eli Lilly and (LLY) Stock Forecast and AI Rating
Forecast targets and rating
Final recommendation
Hold & Monitor
Model signals are balanced; wait for clearer evidence.
1-Year
NEUTRAL$1,272
+4.7%+5.3% incl. dividends5-Year
NEUTRAL$1,789
+47.3%+51.4% incl. dividendsLatest flagship insight
Why the Market Misprices the Massive Capital Intensity of Metabolic Blockbusters
High consensus across reports indicates that while metabolic franchise scaling drives unprecedented top-line velocity, massive capital expenditure and impending multiple compression will limit near-term equity returns. The primary driver is oral formulation commercialization, while the chief risk centers on regulatory pricing caps and margin dilution.
This is the latest published deep-analysis batch. Audit previous forecasts in full transparency
Warren Buffett (Value Purist), Superintelligence (Anthropologist), Ray Dalio (Strategist), Machiavelli (Insider), Elon Musk (Visionary), Michael Burry (Vulture), J.P. Morgan (Titan), Sherlock Holmes (Whistleblower). Some archetypes run in multiple modes, resulting in 12 advisors total.
Research support only. We don't give financial advice.
Gemini
Claude
ChatGPT
GrokExecutive Summary
Dotted terms open concise definitions. Browse technical terms
Interactive forecast chart
The base-case consensus projects robust volumetric earnings expansion for this metabolic leader, offset by structural multiple compressionmultiple compressionA decline in valuation ratios such as price-to-earnings or enterprise-value-to-sales.View full glossary entry as the asset transitions from hyper-growth to a mature, capital-intensive oligopolyoligopolyA market structure dominated by a small number of firms, creating high barriers to entry.View full glossary entry. While the global commercialization of oral formulations dramatically expands the addressable marketaddressable marketAddressable market is the portion of the broader market that a business can realistically target with its offering, geography, and distribution.View full glossary entry and bypasses sterile fill-finish bottlenecks, the massive physical capital intensitycapital intensityA business condition where large upfront spending on assets and infrastructure is needed to operate and grow.View full glossary entry required to scale manufacturing and comply with domestic supply-chain mandates will temporarily suppress free cash flow conversionfree cash flow conversionThe proportion of earnings, EBITDA, or another operating measure converted into free cash flow over a specified period.View full glossary entry. Sophisticated investors must separate spectacular operational execution from equity performance, as high discount rates and competitive entry cap valuation multiples.
Key insights
- Oral small-molecule commercialization bypasses sterile fill-finish bottlenecks, expanding global market penetration and primary care adoption.
- Unprecedented capital expenditurecapital expenditureCapital expenditure (CAPEX) is spending on long-lived assets or major improvements expected to support operations over multiple periods.View full glossary entry builds an insurmountable physical manufacturing moat, locking out sub-scale biotech challengers.
- Structural multiple compressionmultiple compressionA decline in valuation ratios such as price-to-earnings or enterprise-value-to-sales.View full glossary entry from elevated levels toward historical industry norms acts as a persistent anchor on share price appreciation.
- Impending price competition from well-capitalized peers and regulatory pricing frameworks will cap gross margin expansiongross margin expansionAn increase in gross profit as a percentage of revenue.View full glossary entry over the horizon.
- Fortress balance sheetfortress balance sheetA financial position with high liquidity and low debt, providing resilience against market volatility.View full glossary entry strength and robust interest coverage provide absolute downside protection and strategic M&A optionality.
- The core variant perceptionvariant perceptionAn investment view that differs from market consensus and assumes future outcomes will be better or worse than widely expected.View full glossary entry lies in the margin cannibalization of oral formats versus premium injectables.
- High-density computational chemistry and AI integrations compress the R&D iteration loop, structurally lowering long-term drug discovery costs.
Deep Dive
Alpha Gap & Repricing Catalysts
Where does the current market narrative diverge from our AI Forecasts—and what could close the gap?
Market Narrative
What does the market currently expect? The conventional market narrative views the asset as an untouchable, software-like monopoly guaranteed to enjoy perpetual hyper-growth. The crowd anchors heavily on exponential weight-loss prescription curves and headline accounting earnings, assuming the global obesity market will expand seamlessly to hundreds of billions of dollars without pricing degradation. Retail and sell-side analysts largely treat the current high profit marginsprofit marginsProfit margins measure the share of revenue retained as profit after covering specified costs, expressed as a percentage.View full glossary entry as permanent, believing that supply constraints are the only barrier to infinite growth. This euphoric consensus ignores the gravitational pull of capital intensitycapital intensityA business condition where large upfront spending on assets and infrastructure is needed to operate and grow.View full glossary entry, impending price wars, and the political reality of healthcare budget limits.
Alpha Gap
What is the biggest difference between market expectations and our AI forecasts? The core information gap lies in the market's mispricing of the asset's physical capital intensitycapital intensityA business condition where large upfront spending on assets and infrastructure is needed to operate and grow.View full glossary entry and structural margin dynamics. While the crowd focuses on pristine accounting net income, a forensic look reveals massive cash absorption into working capitalworking capitalShort-term operating capital measured as current assets minus current liabilities.View full glossary entry and factory buildouts. The market treats this as an asset-light technology platform, ignoring that scaling biological manufacturing requires heavy industrial capital. Furthermore, the crowd misprices the transition from premium injectables to cheaper oral small-molecules. While modeled as purely additive, the oral pill represents a structural deflationary force that will cannibalize high-margin injectables and compress blended average revenue per useraverage revenue per userAverage revenue per user (ARPU) measures the revenue generated per customer, subscriber, or account over a specified period.View full glossary entry. Finally, the market underappreciates the long-term threat of permanent gene-editing cures that could eventually displace chronic treatment models entirely.
Repricing Catalyst
What could make the market recognize and close that gap? The primary convergence catalyst will be the upcoming earnings cycles in late 2026 and 2027, which will reveal the commercial launch data of the oral formulation. This hard evidence will show whether the cheap oral pill is aggressively cannibalizing high-margin injectable franchises, leading to a collapse in blended average revenue per useraverage revenue per userAverage revenue per user (ARPU) measures the revenue generated per customer, subscriber, or account over a specified period.View full glossary entry. Additionally, Phase 3 clinical readouts from major competitors will break the duopoly illusion, forcing analysts to model heavier pricing concessions and discount the terminal capital expenditurecapital expenditureCapital expenditure (CAPEX) is spending on long-lived assets or major improvements expected to support operations over multiple periods.View full glossary entry run-rate.
Sentiment and Timing
What do sentiment, volatility, and the market-recognition cycle suggest about the thesis timing?
- Greed / Fear
- Greed
- Volatility
- Moderate
- Cycle position
- Overshoot
While there is broad consensus that the asset is in an overshoot phase driven by greed, reports diverge on expected volatility. Some anticipate high, erratic swings due to impending competitive clinical readouts and pricing policy announcements, while others expect moderate, steady volatility supported by robust institutional capitalinstitutional capitalCapital managed by professional institutions such as pension funds, insurers, sovereign funds, endowments, or asset managers.View full glossary entry flows.
Macro Regime Fit
Does the current market environment support the thesis? The macroeconomic regimemacroeconomic regimeThe prevailing set of economic conditions including interest rates and inflation that influence asset pricing.View full glossary entry presents a mixed setup. On one hand, the hawkish Federal Reserve's tight-liquidity, higher-for-longer interest rate environment acts as a severe valuation headwind, penalizing long-duration growth assets and compressing high multiples. On the other hand, the company's software-like gross marginsgross marginsThe percentage of revenue remaining after deducting the direct costs of producing goods sold.View full glossary entry and highly inelastic demandinelastic demandDemand that changes proportionally less than price over a defined range and period.View full glossary entry for metabolic health therapies provide robust stagflationstagflationAn economic condition characterized by stagnant growth, high unemployment, and high inflation.View full glossary entry armor. Consumers prioritize essential healthcare over discretionary spendingdiscretionary spendingConsumer expenditure on non-essential goods sensitive to economic downturns and inflation.View full glossary entry, insulating operational fundamentals from economic downturns and supply-chain shocks.
Advisor Disagreement
What do our AI Advisors disagree about most? The primary disagreement across reports centers on the financial impact of the oral formulation rollout. Some analyses view the oral pill as a highly profitable, additive volume driver that bypasses manufacturing bottlenecks and expands the addressable marketaddressable marketAddressable market is the portion of the broader market that a business can realistically target with its offering, geography, and distribution.View full glossary entry. Conversely, other reports warn that the lower-priced oral format will aggressively cannibalize the high-margin injectable franchise, leading to severe margin dilutiondilutionReduction in ownership percentage for existing shareholders caused by the issuance of new equity shares.View full glossary entry and a collapse in blended average revenue per useraverage revenue per userAverage revenue per user (ARPU) measures the revenue generated per customer, subscriber, or account over a specified period.View full glossary entry. There is also disagreement regarding the timing and severity of valuation multiplevaluation multipleA ratio comparing market or enterprise value with a financial measure such as earnings, revenue, book value, or cash flow.View full glossary entry compression under the current high-rate monetary regimemonetary regimeThe prevailing framework of central-bank policy, interest rates, money creation, and exchange-rate management.View full glossary entry.
Base-Case Forces
Near-certain positive forces
Top Drivers / Tailwinds
Near-certain forces that support the investment thesis. These forces are treated as part of the base case (more than 60% probability of occurrence). Impact columns are specific to this asset class.
Scroll to view all columns
| Driver / Tailwind | Category | Est. stock-price impact | Est. earnings impact | Why it matters |
|---|---|---|---|---|
| Oral Formulation Commercialization | Innovation And Product | +30% | +45% | The fast-tracked oral formulation bypasses complex sterile fill-finish capacity limits and cold-chain logistics. This small-molecule daily pill removes patient needle friction and unlocks mass-market primary care channels globally. By shifting the delivery mechanism, the company dramatically expands its total addressable markettotal addressable marketTotal addressable market (TAM) is the full revenue opportunity available if a product or service achieved complete adoption within its relevant market.View full glossary entry, driving massive volume growth that helps offset unit price compression. |
| Explosive Operating Leverageoperating leverageThe sensitivity of operating profit to changes in revenue caused by the mix of fixed and variable costs.View full glossary entry | Operational Efficiency | +20% | +40% | The company's fixed research and development and administrative bases are clearing, allowing incremental sales of metabolic therapies to drop directly to the bottom line. With gross marginsgross marginsThe percentage of revenue remaining after deducting the direct costs of producing goods sold.View full glossary entry near eighty-four percent, this structural efficiency drives rapid earnings expansion, helping to cushion the stock price against multiple contraction in a high-rate environment. |
| Multi-Indication Moat Expansion | Sector And Industry | +15% | +25% | Clinical validation expanding metabolic therapies into cardiovascular risk reduction, sleep apnea, and liver disease transforms these drugs from discretionary treatments into standard-of-care interventions. This secures long-term insurance and government reimbursement, creating highly inelastic, annuity-like cash flows that protect the business from cyclical economic downturns. |
| Domestic Manufacturing Moat | Competitive Positioning | +10% | +15% | Massive capital expenditurecapital expenditureCapital expenditure (CAPEX) is spending on long-lived assets or major improvements expected to support operations over multiple periods.View full glossary entry dedicated to building domestic active pharmaceutical ingredient and fill-finish facilities creates an insurmountable physical barrier to entry. Under geopolitical decouplinggeopolitical decouplingA reduction in trade, investment, technology exchange, or supply-chain integration between countries or geopolitical blocs.View full glossary entry frameworks, owning secure, localized manufacturinglocalized manufacturingProducing goods within or near the markets where they will be sold.View full glossary entry capacity shields the company from supply-chain disruptions and locks out sub-scale competitors who rely on foreign providers. |
Near-certain negative forces
Top Frictions / Headwinds
Near-certain forces that could slow, cap, or damage the thesis. These forces are treated as part of the base case (more than 60% probability of occurrence). Impact columns are specific to this asset class.
Scroll to view all columns
| Friction / Headwind | Category | Est. stock-price impact | Est. earnings impact | Why it matters |
|---|---|---|---|---|
| Valuation Multiplevaluation multipleA ratio comparing market or enterprise value with a financial measure such as earnings, revenue, book value, or cash flow.View full glossary entry Compression | Macroeconomic And Macrofinancial | -30% | -0.0% | Trading at a rich trailing multiple, the stock faces severe valuation gravityvaluation gravityAn informal expression for the tendency of price to move toward levels supported by earnings, cash flow, or historical valuation norms.View full glossary entry under a restrictive monetary regimemonetary regimeThe prevailing framework of central-bank policy, interest rates, money creation, and exchange-rate management.View full glossary entry. As hyper-growth naturally decelerates due to the law of large numberslaw of large numbersA statistical principle stating that an average tends to approach its expected value as the number of independent observations increases.View full glossary entry, the market will reprice the equity toward historical pharmaceutical norms. This multiple contraction will act as a persistent drag on share price appreciation despite strong earnings. |
| Oral Cannibalization and Margin DilutiondilutionReduction in ownership percentage for existing shareholders caused by the issuance of new equity shares.View full glossary entry | Operational Efficiency | -20% | -20% | The introduction of cheaper oral formulations at lower cash-pay price points will aggressively cannibalize the premium injectable franchise. This deflationary product mix shift guarantees a collapse in blended average revenue per useraverage revenue per userAverage revenue per user (ARPU) measures the revenue generated per customer, subscriber, or account over a specified period.View full glossary entry, meaning that while absolute volumes grow, marginal profitability and overall gross marginsgross marginsThe percentage of revenue remaining after deducting the direct costs of producing goods sold.View full glossary entry will face downward pressure. |
| Populist Pricing and Regulatory Caps | Regulatory | -15% | -15% | As metabolic therapies scale to consume significant portions of healthcare budgets, sovereign governments will enforce aggressive price controlsprice controlsGovernment rules that set, cap, or otherwise constrain the prices charged for specified goods or services.View full glossary entry and rebate demands. Policies targeting pharmaceutical pricing architectures will establish rigid ceilings on net realized prices, limiting the company's ability to extract outsized premiums in its primary markets. |
| Capital-Heavy Manufacturing Drag | Capital Allocation | -10% | -10% | The relentless capital expenditurecapital expenditureCapital expenditure (CAPEX) is spending on long-lived assets or major improvements expected to support operations over multiple periods.View full glossary entry required to construct and maintain complex biological manufacturing facilities acts as a heavy drag on free cash flow conversionfree cash flow conversionThe proportion of earnings, EBITDA, or another operating measure converted into free cash flow over a specified period.View full glossary entry. This physical supply-chain intensity limits near-term cash returns to shareholders, frustrating investors who mistakenly value the business like a frictionless digital platform. |
What Could Break or Accelerate the Thesis
Plausible downside scenarios
Tail Risks
Tail yet plausible downside scenarios selected for their highest potential impact.
Scroll to view all columns
| Tail scenario | Chance of Occurring | Stock Price Impact | Exposure category | Why plausible / what changes |
|---|---|---|---|---|
| Severe Post-Market Safety Signal | 15% | -40% | Regulatory | The emergence of a rare, delayed-onset safety signal in population-scale real-world data could prompt regulatory bodies to issue strict black-box warnings or usage restrictions. This would instantly destroy the drug's mass-market appeal, collapse prescription volumes, and invite massive class-action liabilities. |
| Sovereign Intellectual Propertyintellectual propertyLegally protected intangible creations such as patents, copyrights, trademarks, designs, trade secrets, and proprietary know-how.View full glossary entry Expropriation | 15% | -30% | Political And Geopolitical | Under severe fiscal strain from rising healthcare costs, populist governments might invoke emergency powers, march-in rights, or compulsory licensing to break the company's patents. This would instantly flood the market with cheap generic alternatives, permanently destroying pricing powerpricing powerThe ability of a company to raise prices without losing significant customer demand.View full glossary entry. |
Plausible upside scenarios
Tail Opportunities
Tail yet plausible upside scenarios selected for their highest potential impact.
Scroll to view all columns
| Tail scenario | Chance of Occurring | Stock Price Impact | Exposure category | Why plausible / what changes |
|---|---|---|---|---|
| Universal Sovereign Coverage Mandates | 35% | +25% | Regulatory | If major sovereign health systems and private insurers formally mandate comprehensive, un-gated coverage for metabolic therapies as a preventative measure, the addressable marketaddressable marketAddressable market is the portion of the broader market that a business can realistically target with its offering, geography, and distribution.View full glossary entry will shift from out-of-pocket affluence to total population saturation, unlocking massive guaranteed revenue streams. |
| Neurodegenerative Franchise Breakthrough | 25% | +20% | Innovation And Product | Should next-generation pipeline assets demonstrate definitive, disease-modifying reversal in cognitive decline diseases like Alzheimer's, the company would capture a second, completely distinct multi-billion-dollar market, diversifying its revenue base and driving premium valuation expansion. |
Company Financial Analysis
Eli Lilly and Earnings and Financials Analysis by AI
Financial figures available as of Jul 05, 2026. Only filings and source records available by this analysis date are included.
Earnings and financials
The company is experiencing spectacular financial growth, highlighted by a massive surge in recent revenues and net income. This explosive performance is driven by the incredible global demand for its weight-loss and diabetes treatments. However, experts point out a key issue: the company's actual free cash flow is lagging behind its reported profits. This gap exists because a large amount of cash is currently tied up in building inventory and scaling up operations. While most assessments agree that the underlying business is highly profitable and acts as a great shield against inflation, they disagree on the future outlook. Some believe this hyper-growth will continue smoothly, while others warn that the introduction of cheaper daily pills will soon drag down overall profit margins and slow down revenue growth as the market becomes more crowded.
Revenue, earnings, and cash flow
The table compares up to five fiscal years of revenue, net income, and free cash flow available to this analysis.
| Fiscal year | Revenue | Net income | Free cash flow |
|---|---|---|---|
| 2025 | USD 65.2B | USD 20.6B | USD 9B |
| 2024 | USD 45B | USD 10.6B | USD 414.3M |
| 2023 | USD 34.1B | USD 5.2B | USD -3.2B |
| 2022 | USD 28.5B | USD 6.2B | USD 4.6B |
| 2021 | USD 28.3B | USD 5.6B | USD 5.4B |
Valuation context: historical P/E
The table compares up to five fiscal years of point-in-time valuation evidence available to this analysis.
| Fiscal year | P/E | Earnings basis | Currency basis | Ticker / reporting |
|---|---|---|---|---|
| 2025 | 46.8x | TTM | Native | USD / USD |
| 2024 | 65.8x | TTM | Native | USD / USD |
| 2023 | >100x | TTM | Native | USD / USD |
| 2022 | 55.7x | Annual | Native | USD / USD |
| 2021 | 47.2x | Annual | Native | USD / USD |
P/E uses historical market capitalization and earnings known at each period. Cross-currency observations are normalized to USD using point-in-time FX rates.
Profitability and margins
The company currently boasts outstanding profitability, with gross margins reaching eighty-four percent and operating margins expanding significantly. This software-like profitability reflects immense pricing power and the benefits of scaling up production. However, a major clash exists regarding whether these peak margins are sustainable. Some analysts believe the company can maintain these high margins by shifting to cheaper-to-make oral pills and bypassing traditional middlemen. In contrast, others argue that profit margins have reached their absolute peak and are bound to shrink. They point to upcoming price wars with major rivals, government price controls, and the lower selling price of the new daily pill as forces that will inevitably drag margins down. While the company remains a premier defensive asset, retail investors should expect profit margins to plateau or compress as the market matures.
The table compares up to five fiscal years of operating income and reported profitability margins.
| Fiscal year | Operating income | Operating margin | Net margin |
|---|---|---|---|
| 2025 | USD 29.7B | 45.6% | 31.7% |
| 2024 | USD 17.5B | 38.9% | 23.5% |
| 2023 | USD 10.8B | 31.6% | 15.4% |
| 2022 | USD 8.7B | 30.3% | 21.9% |
| 2021 | USD 7.9B | 28.0% | 19.7% |
Balance sheet and leverage
The company's balance sheet is an absolute fortress, offering incredible safety and financial firepower. With a massive pool of assets and highly manageable debt levels, the company is exceptionally well-positioned to survive any economic downturn or credit market squeeze. Its strong cash-generating power easily covers all interest payments, making it virtually immune to high interest rates. Analysts universally agree that this financial strength provides excellent downside protection for investors. It also gives management the flexibility to fund expensive research, build new factories, and acquire smaller biotech innovators without needing to borrow expensive money. There is very little disagreement here; the consensus is highly unified that the company's financial health is pristine, serving as a powerful shock absorber that allows the business to self-fund its ambitious global expansion plans.
The table compares up to five fiscal years of debt, liquidity, net cash or debt, and current-ratio evidence.
| Fiscal year | Total debt | Cash + short-term investments | Net cash / (debt) | Current ratio |
|---|---|---|---|---|
| 2025 | USD 42.5B | USD 7.3B | USD 35.3B net debt | 1.58x |
| 2024 | USD 33.6B | USD 3.4B | USD 30.4B net debt | 1.15x |
| 2023 | USD 25.2B | USD 2.9B | USD 22.4B net debt | 0.94x |
| 2022 | USD 16.2B | USD 2.2B | USD 14.2B net debt | 1.05x |
| 2021 | USD 16.9B | USD 3.9B | USD 13.1B net debt | 1.23x |
Net debt below zero is displayed as net cash. Current ratio is current assets divided by current liabilities.
Capex and investment intensity
The company is spending historic amounts of money on capital expenditures, dedicating billions to building advanced manufacturing plants. This heavy spending is highly expansionary, aimed at solving chronic supply shortages and constructing a massive physical shield against competitors. Because manufacturing complex weight-loss drugs is incredibly difficult, these factories create a powerful moat that smaller rivals simply cannot afford to replicate. Most assessments agree that this aggressive spending is a smart long-term move that strengthens the company's competitive position, especially as geopolitical rules push for domestic production. However, opinions differ on the near-term impact. Some analysts worry that this heavy spending will keep free cash flow depressed for years, while others expect a rapid payback as soon as these state-of-the-art facilities become fully operational and begin churning out high-volume oral treatments.
The table compares up to five fiscal years of capital expenditure and research-and-development investment.
| Fiscal year | Capital expenditure | R&D spend |
|---|---|---|
| 2025 | USD 7.8B | USD 13.3B |
| 2024 | USD 8.4B | USD 11B |
| 2023 | USD 7.4B | USD 9.3B |
| 2022 | USD 2.5B | USD 7.2B |
| 2021 | USD 1.9B | USD 6.9B |
Quarterly Forecast Scenarios
Eli Lilly and Quarterly Forecast Scenarios
One row per forecast quarter. Asset scenario targets are shown in USD; benchmark values are shown in USD.
Scroll to view all columns
| Timeline | Bear Case Stock Price (USD) | Base Case Stock Price (USD) | Bull Case Stock Price (USD) | S&P 500 benchmark (USD) |
|---|---|---|---|---|
| $1,117 | $1,225 | $1,275 | $736.09 | |
| $982.78 | $1,239 | $1,364 | $724.14 | |
| $835.36 | $1,229 | $1,378 | $713.57 | |
| $751.83 | $1,272 | $1,447 | $723.38 | |
| $691.68 | $1,305 | $1,514 | $716.61 | |
| $657.10 | $1,342 | $1,590 | $738.34 | |
| $617.67 | $1,355 | $1,702 | $746.91 | |
| $592.96 | $1,371 | $1,676 | $771.93 | |
| $604.82 | $1,379 | $1,731 | $782.73 | |
| $574.58 | $1,427 | $1,887 | $807.31 | |
| $557.35 | $1,461 | $1,982 | $822.72 | |
| $579.64 | $1,502 | $2,061 | $846.10 | |
| $591.23 | $1,531 | $2,123 | $852.53 | |
| $579.41 | $1,580 | $2,271 | $882.91 | |
| $596.79 | $1,608 | $2,158 | $900.46 | |
| $620.66 | $1,617 | $2,287 | $922.67 | |
| $633.07 | $1,648 | $2,470 | $935.91 | |
| $614.08 | $1,692 | $2,594 | $952.30 | |
| $632.50 | $1,741 | $2,749 | $976.28 | |
| $645.15 | $1,789 | $2,942 | $1,002 |
Research Provenance
References & Context
This Eli Lilly and consensus analysis combines structured market evidence with independent AI-agent forecasts. External references below are limited to sources recorded by the researcher agents for this forecast batch.
Primary analysis inputs
- iPulse AI Multi-Agent Forecasts — independent analyst personas, model outputs, and consensus synthesis.
- iPulse AI Global Events Context — macroeconomic, geopolitical, regulatory, and industry-event context.
- Structured market history — prices, distributions, volatility, identifiers, and listing metadata.
- Company earnings and financial statements — revenue, profitability, balance-sheet, cash-flow, and investment trends.
- Researcher web evidence — public sources consulted to challenge and contextualize the forecast thesis.
Independent AI Advisor panel
- AI Advisors
- 12
- AI Researchers
- 7
- AI Thinkers
- 5
Sources retained from AI Researcher searches
Showing the top 1 of 1 deduplicated sources retained for this batch.
Some model providers retained only the consulted domain, not an exact article URL. Those domains are shown as evidence without inventing a link.
- 01lilly.comlilly.com
Context retained with this Consensus
The same public-safe market, global-event, and fundamental context supplied to the AI Advisor panel.
Global context snapshot
2025 Full-Year Global Market and World-Events Context
Download Archived SnapshotCoverage 2025-01-01 to 2025-12-31 · Knowledge cutoff 2025-12-31
- File size
- 90.8K bytes
- Words
- 12.8K words
- Characters
- 90.8K characters
This full-year context package covers the principal geopolitical, economic, monetary-policy, technology, trade, energy, and institutional developments that shaped global markets during 2025. It gives the forecasting model a chronological account of major world events together with their likely transmission into growth, inflation, interest rates, supply chains, commodities, currencies, public markets, and sector-level investment conditions.
The package also includes monthly and quarterly macroeconomic and cross-asset reference tables spanning US and international growth, central-bank policy, sovereign yields, major equity indices, foreign exchange, energy, industrial and precious metals, and digital assets. Quarterly and full-year high-impact summaries are integrated; monthly quantitative series remain working values pending final audit, and that qualification is part of the preserved context.
| Top 3 Market Shifts From File | Date | Status |
|---|---|---|
| DeepSeek shock and AI economics reset | 2025-01-27 | OPEN ENDED TREND |
| US tariff regime escalation and trade-system rupture | 2025-02-01 | ACTIVE POLICY REGIME |
| Federal Reserve easing cycle after a prolonged hold | 2025-09-17 | ACTIVE POLICY REGIME |
Representative Sources of the Context File
And more sources from the retained context package.
2026 Year-to-Date Global Market Context through 2026-05-31
Download Archived SnapshotCoverage 2026-01-01 to 2026-05-31 · Knowledge cutoff 2026-05-31
- File size
- 78K bytes
- Words
- 10.9K words
- Characters
- 78K characters
This year-to-date package described the geopolitical, macroeconomic, monetary-policy, technology, trade, energy, and cross-asset developments available through the batch knowledge cutoff of 2026-05-31.
It supplied dated market and policy context, including rates, sovereign yields, equities, foreign exchange, energy, metals, and digital assets, for the forecast generation workflow.
| Top 3 Market Shifts From File | Date | Status |
|---|---|---|
| The Iran and Strait of Hormuz conflict shocked energy markets | 2026-02-28 | STARTED AND ONGOING |
| U.S. monetary policy entered the Warsh transition | 2026-01-30 | STARTED AND ACTIVE POLICY TRANSITION |
| Agentic AI and infrastructure spending kept expanding | 2026-01-01 | OPEN ENDED |
Representative Sources of the Context File
And more sources from the retained context package.
Fundamental context
Income statement
34 fieldscostOfRevenue · currency_symbol · date · depreciationAndAmortization · +30 more fields
Balance sheet
64 fieldsaccountsPayable · accumulatedAmortization · accumulatedDepreciation · accumulatedOtherComprehensiveIncome · +60 more fields
Cash flow
32 fieldsbeginPeriodCashFlow · capitalExpenditures · cashAndCashEquivalentsChanges · cashFlowsOtherOperating · +28 more fields
Outstanding shares
4 fieldsdate · dateFormatted · shares · sharesMln
annual: 2007-01-01–2026-01-01, 20 periods; quarterly: 2023-06-30–2026-03-31, 12 periods
Currencies cited: USD (quote USD; primary reporting USD; converted/valuation USD).